MedTrace Logo

Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients

NCT07147465 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3149

Last updated 2025-08-29

No results posted yet for this study

Summary

As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.

The SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records.

This cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.

Conditions

Sponsors & Collaborators

  • AuraGen Aesthetics LLC

    collaborator INDUSTRY

  • Centre Leon Berard

    collaborator OTHER

  • Laboratoire SeqOIA

    collaborator UNKNOWN

  • PLAN FRANCE MÉDECINE GÉNOMIQUE 2025

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Isabelle DURAND-ZALESKI, Professor · Greater Paris University Hospitals

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-07-31
Completion
2026-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07147465 on ClinicalTrials.gov